PAH treatment options widen

The number of treatment options available to adults with pulmonary arterial hypertension (PAH) could increase under draft NICE guidance.

NICE preliminary guidance recommends the use of endothelin receptor antagonists for the treatment of PAH.

Currently, only supportive care, such as anticoagulants, diuretics and calcium channel blockers, are available for those suffering from PAH.

NICE recommends use of sildenafil and, if the treatment is contraindicated or poorly tolerated, bosentan and sitaxentan could be prescribed.

NICE will conduct a second appraisal meeting next month to consider any feedback from the preliminary recommendations.

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus
Follow Us: